While high-intensity statin therapy is supported by guidelines for patients with atherosclerotic cardiovascular disease (ASCVD), many patients don’t end up being prescribed these medicines for reasons ...

5 In adults with multiple ASCVD risk factors, initiate high-intensity statin to reduce LCL-C by ≥50%. In adults with 10-year ASCVD risk ≥20% who are on maximally tolerated statin therapy, may ...

Goal Is Not Reflexive High-Intensity Statin Rx . In an editorial accompanying the study, Neil Stone, MD (Northwestern University Feinberg School of Medicine, Chicago, IL), one of the lead authors the ...

High-intensity, moderate-intensity, and low-intensity statin therapies lower LDL-C levels by ≥50%, 30% to 49%, and <30%, respectively. Recommended statin regimens for each intensity level include: ...

The 2013 American College of Cardiology/American Heart Association cholesterol guidelines recommend high-intensity statins for secondary prevention in ASCVD patients 75 years and younger but only ...

Women were less likely to fill a prescription for high-intensity statins after hospitalization for MI compared with men, according to a study published in the Journal of the American College of ...

Although medical guidelines recommend high-intensity statins for nearly all people with established cardiovascular disease, previous studies have shown that rates of guideline compliance are low.

The guidelines also suggest that statins should be prescribed in the maximum dose tolerable, and encourage the prescription of high-intensity, high-dose statins for many benefit groups.

Perhaps prescribing physicians aren't heeding evidence that, regardless of LDL-C, such patients benefit more from high-intensity compared with low-intensity statins, researchers propose.

In patients with atherosclerotic cardiovascular disease, study authors from Stanford University found that those who received high-intensity statins had the biggest reduction in mortality risk.

From 2011 to 2014 the use of high-intensity statins following hospitalization for myocardial infarction (MI) increased progressively, according to a study published in Journal of the American ...

Compared with a placebo, the addition of the injectable cholesterol-lowering drug alirocumab to high-intensity statin treatment in patients who have had a heart attack resulted in twofold greater ...